Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Stiripentol - Biocodex

Drug Profile

Stiripentol - Biocodex

Alternative Names: BCX 2600; Diacomit; ME-2080

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocodex
  • Developer Biocodex; Meiji Seika Pharma
  • Class Antiepileptic drugs; Dioxolanes; Neuroprotectants
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myoclonic epilepsies
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myoclonic epilepsies

Most Recent Events

  • 12 Feb 2019 Biocodex initiates a phase I trial (In volunteers) in Belgium (NCT03866928)
  • 01 Feb 2019 Biocodex plans a phase II trial for Hyperoxaluria (Monotherapy) (NCT03819647)
  • 23 Aug 2018 Biocodex intends to launch Stiripentol for Myoclonic epilepsies in USA in January 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top